The main drag is fading
- Q1 2026 showed the U.S. Group healthcare block performing in line with management's 2026 expectations.
- RGA bought back $50M of stock and deployed $338M into in-force transactions in the quarter.
- The company has built $343M of favorable economic claims experience since 2023, which could help future earnings.
- Asia Pacific and EMEA remain key growth areas, helped by asset-intensive deals and longevity business.
- The bear case now depends more on credit markets, private credit, and a surprise turn in mortality trends.
A cleaner earnings story
RGA looks less risky than it did a few quarters ago. The main reason is U.S. Group healthcare. That block hurt results in 2025, but management said Q1 2026 results were in line with its 2026 expectations after repricing. That removes the biggest company-specific worry in the current thesis.
The bull case is now simpler. RGA has a global life and health reinsurance franchise, plus a growing financial solutions business. It is putting capital to work in deals, especially in Asia, while also buying back stock. In Q1 2026, it repurchased $50M of shares and deployed $338M into in-force transactions.
Claims have also been better than expected in economic terms. Since 2023, cumulative favorable claims experience is $343M. Management expects only part of that benefit to show up each year, so the open question is how fast it flows into reported earnings.
The bear case is not gone. A credit market shock could hurt the investment portfolio, including private credit at about 9% of total assets. A sharp reversal in mortality, or a sudden pause in global deal flow, would also weaken the thesis.
Paid to take hard risks
RGA is a reinsurer. That means it takes some risk from insurance companies in exchange for premiums, fees, or investment spread. In plain terms, insurers pay RGA to carry part of the chance that people die, get sick, live longer than expected, or that asset returns fall short.
The company makes money in two main ways. Traditional life and health reinsurance earns premiums over long periods, often 10 to 30 years or more. Financial solutions earns fees, investment income, and spreads from asset-intensive reinsurance, longevity deals, pension risk transfer, and capital solutions.
Management calls its main strategy the Creation Re flywheel. The idea is to work with clients on tailored products instead of bidding in crowded markets. Management has said this strategy now drives over 50% of new business.
Where it breaks is simple to name but hard to forecast. If claims are priced wrong, if credit losses rise, or if RGA pays too much for large blocks of business, earnings can fall fast. The company is strong when its risk selection is better than the market's.
What RGA sells
Traditional life and health reinsurance
This covers mortality and morbidity risks, meaning death and health claims. It is long-duration business, so pricing discipline matters a lot.
Asset-intensive reinsurance
RGA takes on both insurance liabilities and assets that support them. This is a sweet spot in Asia because it uses both asset management and biometric skill.
Pension risk transfer and longevity swaps
RGA helps pension plans or insurers manage the risk that people live longer than expected. This is active in the U.S., U.K., and Canada.
Financial solutions and capital reinsurance
These deals help clients manage capital rules and balance sheets. Some are lower-risk fee businesses, but fees can move with deal timing.
Long-term care blocks
RGA takes long-term care risk only when a block is modest in size and fits an existing client relationship. This can add profit, but the line is known for claim uncertainty.
A global book
The mix uses Q1 2026 total segment revenues for operating regions, excluding Corporate and Other. Segment revenue can move with currency, large deals, and client reporting.
What could break it
Claims turn against the model
High impact · Medium oddsRGA prices risks like death, illness, disability, and longevity. Claims can look smooth over many years but swing hard in one quarter. Q1 2026 was favorable overall, but that can reverse.
U.S. Group healthcare relapse
Medium impact · Low oddsThis was the key overhang in 2025. Management fully repriced the block for 2026 and said Q1 results were in line with expectations. The risk is that medical claims rise again before the company fully exits the line after 2027.
Credit market shock
High impact · Medium oddsRGA holds a large investment portfolio to back its promises. A severe credit downturn could cause impairments, lower capital flexibility, and hurt earnings. Private credit is about 9% of total assets, so its performance deserves attention.
Deal returns get bid down
Medium impact · Medium oddsGrowth depends on finding attractive in-force, asset-intensive, and longevity deals. If competitors accept lower returns, RGA may either lose deals or accept thinner margins. Asia is a key market to watch because it is both attractive and competitive.
Currency cuts reported results
Medium impact · Medium oddsRGA earns a meaningful share of profit outside the U.S. Changes in the British pound, Canadian dollar, euro, and Asian currencies can move reported results. In Q1 2026, currency helped adjusted operating income before taxes by $17M.
In one breath
What does RGA actually do?
RGA reinsures life and health insurance risks for other insurers. It also helps insurers and pension plans manage asset, capital, and longevity risks.
Why did U.S. Group healthcare matter so much?
That block had unfavorable claims in 2025 and became the main earnings worry. Management repriced it for 2026, and Q1 results matched expectations, so the issue looks much less serious now.
Why does the investment portfolio matter for RGA?
RGA invests assets that support long-term insurance promises. Investment income helps earnings, but credit losses or market stress can hurt capital and reported profit.